RxDoctor Payments Data

Robert Neuwirth, MD

Nephrology · Gillette, WYNPI 1891726626

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 8 manufacturers, the largest accounting for just 21.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $89 and has fallen 86.7% since, to $12 in 2022.

$181in general payments, 2019–2025

Across 13 payments — averaging $13.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$39
  • GSK$35
  • E.r. Squibb & Sons, L.L.C.$26
  • Sanofi-aventis U.S. LLC$24
  • Novo Nordisk$19
  • AbbVie$13
  • plus $25 from 2 others

What the payments were for

  • Food & beverage$181100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few nephrology providers in Wyomingto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$37,768
Medicare patients
247
Services billed
344

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide13$14,186
Pantoprazole Sodium26$817
Metoprolol Succinate12$733
Ventolin HfaAlbuterol Sulfate12$691
Rosuvastatin Calcium32$589
Gabapentin39$542
Levothyroxine Sodium47$424
Spironolactone19$417
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen13$415
Cyclobenzaprine Hcl14$390
Pregabalin15$315
Amlodipine Besylate36$305
Lisinopril19$287
Metformin Hcl24$282
Sertraline Hcl21$200

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$19$14,18613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few nephrology providers in Wyomingon file to place this against a meaningful peer group, so we don't.

Other nephrology in Gillette

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →